Sep 12, 2025
COPD management has progressively centered on bronchodilator-based regimens, with Long-acting Muscarinic Antagonists (LAMAs) and Long-acting Beta-agonists (LABAs) forming the therapeutic core. Dual LAMA/LABA therapy is standard for moderate disease, while triple therapy with Inhaled Corticosteroids (ICS) is reserve...
Read More...
May 31, 2023
DUPIXENT has shown positive pivotal results for COPD, confirming the key role of IL-4 and IL-13 in type 2 inflammatory diseases. DUPIXENT has the potential to be the first biologic with unprecedented and paradigm-shifting clinical results to treat COPD, having demonstrated a statistically significant reduc...
Read More...
Apr 08, 2022
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death across the globe. It is a widespread, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow restriction caused by airway and alveolar abnormalities, which are mainly induced by prolonged exposu...
Read More...
Nov 15, 2019
Levels of air pollution have risen dramatically over the past years due to increasing outdoor human activities such as industrialization, urbanization and indoor activities like burning of solid fuels, coal, etc. This has contaminated the air we breathe with several harmful substances such as Sulfur dioxide (SO2), ...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper